AbbVie’s investigational drug tavapadon, a D1/D5 dopamine receptor partial agonist, demonstrated positive results in a Phase 3 trial for early Parkinson’s disease. The drug showed a statistically significant improvement in motor function and quality of life compared to placebo in patients with early Parkinson’s disease.
AbbVie is set to release its first-quarter earnings results on Friday, April 26th, before the market opens. Analysts anticipate a profit of $2.26 per share, an 8.1% decrease year-over-year, on revenue of $11.94 billion, a 2.4% decline from the same period last year. Investors will be particularly interested in the company’s comments regarding its strategy for addressing Humira’s biosimilar challenges and its post-Humira growth prospects, as well as any updates on pricing trends for the upcoming quarters.
Dividend investing has a proven track record of outperforming non-dividend-paying stocks, leading many investors to rely on Dividend Aristocrats. However, focusing solely on the duration of dividend increases is insufficient.
To ensure sustained dividend growth, investors should consider companies that can generate sufficient free cash flow (FCF) to support their payouts. This article highlights seven dividend growth stocks with strong FCF that can maintain their dividend payments.
LVMH, UnitedHealth Group, Dick’s Sporting Goods, Domino’s, AbbVie, Automatic Data Processing, and Home Depot are all recommended as potential investments. These companies have demonstrated consistent dividend growth, high FCF generation, and resilience to economic challenges.
